Global pharmaceutical giant GlaxoSmithKline showcased its leading medical solutions at the CIIE
Under the warm attention of the world, GlaxoSmithKline, as a global pharmaceutical giant, recently made a wonderful appearance at the 6th China International Import Expo (hereinafter referred to as the Expo), revealing its leading position in the field of medical and health care. The first roundtable research meeting co-hosted with Xinhuanet, with the theme of "Healthy Aging and Prevention First", put on the stage how to deal with the challenges of population aging and promote high-quality health management.
Preventive medicine has been widely recognized as a key step in addressing the health problems of aging populations in addressing the challenges of population aging. The World Health Organization has even rated vaccination as one of the most successful and cost-effective public health initiatives in the world. Combined with a thorough vision and careful and thoughtful planning, this seminar has had a profound impact on the realization of the "Healthy China 2030" strategy.
The recombinant herpes zoster vaccine on display is undoubtedly a major focus of the Expo. The vaccine, designed for the elderly over 50 years old, has been available at 9,500 vaccination sites in 314 cities since it was approved in China in May 2019 and was officially launched in 2020. It is the popularity and use of this product that enables the elderly to reduce the infection rate of a variety of diseases, thereby reducing the medical burden and improving the quality of life.
Bixia Feng, Head of GlaxoSmithKline's China Vaccine Business, shared the launch journey of GlaxoSmithKline and proudly announced that GlaxoSmithKline is currently developing 23 vaccine candidates. This is not only an announcement of achievement, but also a determination to move mountains. GlaxoSmithKline has always been committed to putting patients at the centre of our lives and is fully committed to leveraging innovative technologies to deliver better and more cost-effective healthcare solutions to patients around the world.
At the GlaxoSmithKline and Xinhuanet's roundtable seminar, we discussed how to integrate various resources and advantages to build a prevention and treatment system for aging diseases. This effort indicates that GlaxoSmithKline has actively responded to and permeated the concept of prevention first, so as to promote high-quality health management of the middle-aged and elderly population"Healthy China 2030"Realization of the strategy.
With GlaxoSmithKline's leading vaccine products, technological innovation capabilities, and its in-depth focus and research on an aging society, it will surely shape more promising possibilities in the future healthcare industry. It is expected that with the joint efforts of GlaxoSmithKline and many companies investing in the field of public health around the world, the realization of the vision of "Healthy China 2030" will not be far away.